CINECA IRIS Institutional Research Information System

DRANDI, Daniela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.340
EU - Europa 3.212
AS - Asia 1.058
AF - Africa 79
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 13
SA - Sud America 10
Totale 8.727
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.286
CN - Cina 706
IT - Italia 601
DE - Germania 500
SE - Svezia 462
IE - Irlanda 366
AT - Austria 303
UA - Ucraina 243
FR - Francia 231
FI - Finlandia 182
KR - Corea 144
PL - Polonia 88
GB - Regno Unito 76
SN - Senegal 72
CA - Canada 46
VN - Vietnam 44
SG - Singapore 40
IN - India 33
BE - Belgio 30
ES - Italia 27
GR - Grecia 27
SA - Arabia Saudita 22
RU - Federazione Russa 21
JP - Giappone 19
NL - Olanda 19
AU - Australia 14
EU - Europa 13
HK - Hong Kong 12
UZ - Uzbekistan 12
BY - Bielorussia 9
BR - Brasile 8
IR - Iran 8
CH - Svizzera 5
MX - Messico 5
ID - Indonesia 4
CZ - Repubblica Ceca 3
NO - Norvegia 3
PK - Pakistan 3
PT - Portogallo 3
RO - Romania 3
TW - Taiwan 3
ZA - Sudafrica 3
BG - Bulgaria 2
HU - Ungheria 2
LU - Lussemburgo 2
PR - Porto Rico 2
TR - Turchia 2
BD - Bangladesh 1
CO - Colombia 1
CU - Cuba 1
DK - Danimarca 1
DZ - Algeria 1
EG - Egitto 1
GH - Ghana 1
IL - Israele 1
KH - Cambogia 1
KW - Kuwait 1
LV - Lettonia 1
MD - Moldavia 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PH - Filippine 1
RS - Serbia 1
SC - Seychelles 1
UY - Uruguay 1
Totale 8.727
Salva come PNG Salva come JPEG
Città #
Chandler 709
Beijing 531
Dublin 365
Vienna 303
Ashburn 250
Jacksonville 207
Ann Arbor 203
Fairfield 197
Nyköping 178
Dearborn 163
Houston 162
Torino 158
Villeurbanne 125
Medford 124
Woodbridge 123
Wilmington 121
San Mateo 107
Princeton 106
Seattle 79
Warsaw 79
Florence 68
Cambridge 64
Fremont 63
Turin 46
Redwood City 45
Pisa 44
Washington 39
Toronto 33
Boardman 28
Brussels 28
Boston 27
Norwalk 27
Dong Ket 24
Milan 21
Nürnberg 21
Düsseldorf 19
Nanjing 18
New York 16
Philadelphia 15
Seongnam 15
Bologna 14
Hefei 14
Munich 14
Shanghai 13
Los Angeles 12
Mountain View 12
Chennai 11
Redmond 10
Rome 10
Helsinki 9
Rotterdam 9
San Diego 9
Tokyo 9
Zhengzhou 9
Guangzhou 8
Hangzhou 8
Hebei 8
Ottawa 8
Paris 8
San Mauro Torinese 8
Chengdu 7
Jinan 7
Kunming 7
Saint Petersburg 7
Des Moines 6
Falls Church 6
Phoenix 6
San Francesco 6
Perth 5
Pune 5
San Jose 5
Tianjin 5
Volpago Del Montello 5
Columbus 4
Dallas 4
Hong Kong 4
Linden 4
Liverpool 4
Margherita Di Savoia 4
Mcallen 4
Provo 4
Seoul 4
Singapore 4
Xian 4
Auburn Hills 3
Barcelona 3
Bari 3
Brescia 3
Bucharest 3
Changchun 3
Changsha 3
Costa Mesa 3
Duncan 3
Forcoli 3
Heidelberg 3
Jakarta 3
Jeddah 3
Johannesburg 3
Leawood 3
Limoges 3
Totale 5.323
Salva come PNG Salva come JPEG
Nome #
IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells 269
Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma 246
MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients 204
Prospective molecular monitoring of minimal residual disease after nonmyeloablative allografting in newly diagnosed multiple myeloma 192
The Defective Proliferation of Vgamma9Vdelta2 T Cells to Zoledronic Acid In Chronic Lymphocytic Leukemia (CLL) Is a Powerful Time to First Treatment (TFT) Predictor Associated with the IGHV Mutational Status. 190
Highly sensitive MYD88 l265p mutation detection by droplet digital polymerase chain reaction in waldenström macroglobulinemia 186
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis 178
Centralized Biobanking Supports Hematology Clinical Trials: the new challenge of the University of Torino 174
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis 161
Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells 152
Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia 132
New Molecular Technologies for Minimal Residual Disease Evaluation in B-Cell Lymphoid Malignancies 121
High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma 120
Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: evidence for premature aging of the myeloid compartment. 120
Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA) 119
High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma 114
EXPRESSION OF MET MRNA AS PROGNOSTIC MARKER IN MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL DRUGS 112
The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL) 112
TELOMERES SHORTEN DURING CHRONIC LYMPHOCYTIC LEUKEMIA(CLL) EVOLUTION: AN ANALYSIS ON 88 CASES 110
Telomere Length Identifies Two Distinct Populations with Different Outcome among VH-Unmutated CLL Patients 107
Cyclooxygenase-2 (COX-2) Is Frequently Expressed in Multiple Myeloma (MM) and Is Associated with Poor Outcome 105
IDENTIFICATION BY SEROLOGICAL PROTEOME ANALYSIS (SERPA) OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) 104
Ficoll-hypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis 104
Characteristics of the Immunoglobulin Heavy Chain (IgH) Rearrangement in Multiple Myeloma (MM): An Analysis On 308 Cases 103
The Mevalonate Pathway As a Metabolic Target to Circumvent Multidrug-Resistance in Chronic Lymphocytic Leukemia Cells 103
Long-Term Monitoring of Cancer-Free Subjects Carrying Non-Lymphoma Associated bcl2/IgH Rearrangements (NLABR): Prolonged Persistence of Clonal Populations Potentially Related to Follicular Lymphoma (FL) 101
Phenotypic and Functional Features of V{gamma}9/V{delta}2 T Cells in Chronic Lymphocytic Leukemia Are Strongly Correlated with the Mutational Status of the Immunoglobulin Heavy Chain Variable Region (IgVH) and Metabolic Activity of the Mevalonate Pathway in Tumor Cells 100
Progressive Telomere Shortening Is Part of the Natural History of Chronic Lymphocytic Leukemia (CLL) and Impacts Clinical Outcom 98
Cells carrying nonlymphoma-associated bcl-2/IgH rearrangements (NLABR) are phenotypically related to follicular lymphoma and can establish as long-term persisting clonal populations 97
THE LOCAL MICROENVIRONMENT PLAYS A DIFFERENT ROLE IN THE SURVIVAL OF TUMOR CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA WITH MUTATED AND UNMUTATED IMMUNOGLOBULIN (IG) VH GENES 96
MYD88L265P MUTATION DETECTION IN WALDENSTRÖM MACROGLOBULINEMIA BY DROPLET DIGITAL PCR: MINIMAL RESIDUAL DISEASE MONITORING AND CHARACTERIZATION ON CIRCULATING FREE DNA 94
Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR 94
Correlation Between Clinical Outcome and Disease Kinetics by Quantitative PCR in Myeloma Patients Following Post-Transplant Consolidation with Bortezomib, Thalidomide and Dexamethasone 92
Targeting the mevalonate pathway and downstream signaling pathways as a strategy to circumvent multidrug-resistance in CLL cells 92
Met Over-Expression Is a Prognostic Factor for Myeloma Patients Treated with Novel Agents 91
Droplet digital PCR for minimal residual disease detection in mature lymphoproliferative disorders 91
Immunoglobulin (Ig) Repertoire in Multiple Myeloma: High Frequency of Recurrent Aminoacid Substitutions in the FR2 and CDR2 90
PROGRESSIVE TELOMERE SHORTENING DURING THE NATURAL HISTORY OF CHRONIC LYMPHOCYTIC LEUKEMIA 90
Telomere Length Is An Independent Predictor of Survival, Treatment Requirement and Richter’s Syndrome Transformation in Chronic Lymphocytic Leukemia 89
Accelerated activity of the mevalonate pathway supports the immune escape and multidrug-resistance phenotype of IGHV unmutated chronic lymphocytic leukemia cells 89
Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival 89
Serological Proteome Analysis (SERPA) as a tool for the identification of novel tumor antigens in chronic lymphocytic leukemia (CLL) 89
IMPACT OF THE MEVALONATE PATHWAY AND HIF/PGP AXIS IN MODULATING MULTIDRUG-RESISTANCE IN UNMUTATED CLL CELLS 88
IGHV Unmutated Chronic Lymphocytic Leukemia (CLL) B Cells Are More Susceptible to Spontaneous Apoptosis Than Mutated CLL B Cells and Are Subject to the Anti-Apoptotic Effect of Environmental Signals 87
Telomere lenght measurement in the clinically oriented research setting: a comparison between Southern blot (SB), real time quantitative PCR (RQ-PCR) and FLOW-FISH (FF) 87
The metabolism of mevalonate as a signaling pathway influencing tumor-host interactions and disease progression in chronic lymphocytic leukemia (CLL) 87
Telomere length is an independent predictor of survival, treatment requirement and Richter’s syndrome transformation in chronic lymphocytic leukemia 87
p29ING4 Regulates the Production of Pro-Angiogenic Molecules by Human Myeloma Cells in Normoxic and Hypoxic Conditions Being Involved in Myeloma-Induced Angiogenesis 85
Telomerase Inhibitor BIBR1532 Induces Telomere Shortening and Growth Inhibition in Extra-Germinal Center (GC)-Derived Lymphoid Cell Lines 84
Differential Effects of Microenvironmental Elements On Tumor Cells Survival in Chronic Lymphocytic Leukemia Patient Subsets with Good or Poor Prognosis 83
Progressive telomere shortening occurs during the natural history of chronic lymphocytic leukemia (CLL) and associates to outcome 83
High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma 83
Expression of telomeric proteins in chronic lymphocytic leukemia (CLL) 82
Identification by serological proteome analysis (SERPA) of novel tumor associated antigens in chronic lymphocytic leukemia (CLL) 81
Central nervous system relapse in a patient with mantle cell lymphoma in continuous clinical and molecular remission at six years since autografting. 80
null 80
High Expression of mRNA and Gene Amplification of Met In Myeloma Plasma Cells Characterize a More Aggressive Disease 80
Identification by serological proteome analysis (SERPA) of tumor-associated antigens eliciting antibody-responses in chronic lymphocytic leukemia 79
SEROLOGICAL PROTEOME ANALYSIS (SERPA) FOR THE IDENTIFICATION OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY-RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA 79
Droplet Digital PCR Assay for MYD88L265P 77
A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients. 76
Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: Evidences from long term follow-up 76
Consolidation with Bortezomib, Thalidomide and Dexamethasone Induces Molecular Remissions in Autografted Multiple Myeloma Patients 75
LONG-TERM RESULTS of the GIMEMA VTD Consolidation TRIAL In Autografted MULTIPLE Myeloma PATIENTS (VEL-03-096): IMPACT of Minimal RESIDUAL DISEASE Detection by REAL Time Quantitative PCR On LATE Recurrences and Overall SURVIVAL 73
Telomere length correlates with histopathogenesis according to the germinal center in mature B-cell lymphoproliferative disorders 72
Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma 71
Major Shrinking of Residual Tumor Cell Burden and Achievement of Molecular Remissions in Myeloma Patients Undergoing Post-Trasplant Consolidation with Bortezomib, Thalidomide and Dexamethasone: A Qualitative and Quantitative PCR Study 71
Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network 71
Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome 70
THE SURVIVAL OF TUMOR CELLS IN IGVH UNMUTATED CHRONIC LYMPHOCYTIC LEUKEMIA IS HIGHLY DEPENDENT ON EXOGENOUS SIGNALS DELIVERED BY THE TUMOR MICROENVIRONMENT 68
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes 68
PHENOTYPIC AND FUNCTIONAL FEATURES OF VGAMMA9/VDELTA2 T CELLS CORRELATE WITH THE MUTATIONAL STATUS OF THE TUMOR IMMUNOGLOBULINE AND WITH DISEASE AGGRESSIVENESS IN CHRONIC LYMPHOCYTIC LEUKEMIA 68
Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: Diagnostic challenges and therapeutic options: Two case reports 68
Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders 67
Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia 67
null 64
Impact of Early Consolidation with Bortezomib, Thalidomide and Dexamethasone on Molecularly-Detectable Disease in MM Patients in CR or VGPR Following Autologous Transplantation: Uncommon Achievement of Molecular Remission Despite Evidence of Tumor Load Reduction by Real Time PCR 62
Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients 61
SEROLOGICAL PROTEOME ANALYSIS (SERPA) FOR THEIDENTIFICATION OF NOVEL TUMOR-ASSOCIATED ANTIGENS INCHRONIC LYMPHOCYTIC LEUKEMIA 61
PCR-detectable non-neoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis, but rare in subjects treated with chemotherapy. 60
IGHV UNMUTATED CLL B CELLS ARE MORE PRONE TO SPONTANEOUS APOPTOSIS AND DEPEND FROM THE ANTI-APOPTOTIC EFFECT OF ENVIRONMENTAL SIGNALS 58
Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma 56
Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms 53
Differential regulation of gene expression following CD40 activation of leukemic compared to healthy B cells 52
COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC LYMPHOCYTIC LEUKEMIA 49
Droplet digital PCR quantification of mantle cell lymphoma follow-up samples from four prospective trials of the european MCL network 49
High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). 46
Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: A phase II clinical trial of the fondazione italiana linfomi 45
Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma 44
Telomere length correlates with histopathogenesis according to the germinal center in mature B-cell lymphoproliferative disorders 40
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma 40
Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase III trial in mantle cell lymphoma 40
Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone. 38
High-Risk Fludarabine-Pretreated B-Cell Chronic Lymphocytic Leukemia's High Response Rate Following Sequential DHAP and Alemtuzumab Administration Though in Absence of Molecular Remission 38
MYD88L265P Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation 38
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma 37
Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights 35
Case Report: Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights 33
A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial 28
Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone. 27
Totale 8.927
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.161
article - articoli 0
book - libri 0
conference - conferenze 11.930
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.091
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019264 0 0 0 0 0 0 0 0 0 0 164 100
2019/20201.137 25 36 27 169 67 178 164 83 78 104 108 98
2020/20211.113 147 68 64 46 131 43 73 59 120 89 156 117
2021/20221.428 41 26 32 117 59 38 249 91 32 149 342 252
2022/20232.011 184 211 48 212 178 486 127 134 208 86 78 59
2023/2024666 106 176 71 40 42 140 10 53 3 25 0 0
Totale 9.046